Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 222
- Registration Number
- NCT00065351
- Locations
- 🇺🇸
Providence St. Joseph Medical Center/Cancer Center, Burbank, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 148
- Registration Number
- NCT00065156
- Locations
- 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Desert Hematology & Oncology Medical Group, Rancho Mirage, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
- First Posted Date
- 2003-07-17
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 215
- Registration Number
- NCT00064974
- Locations
- 🇺🇸
Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸Midwest Cancer Research Group, Skokie, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
- Conditions
- Plasma Cell NeoplasmMultiple Myeloma
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 198
- Registration Number
- NCT00064038
- Locations
- 🇺🇸
William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
🇺🇸Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
- Conditions
- MelanomaNeoplasm Metastasis
- First Posted Date
- 2003-04-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 274
- Registration Number
- NCT00057616
- Locations
- 🇦🇺
Royal Newcastle Hospital, Newcastle, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺Royal Hobart Hospital, Hobart, Tasmania, Australia
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 353
- Registration Number
- NCT00056160
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Clinical Research Consultants, Inc., Hoover, Alabama, United States
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
- Conditions
- LymphomaSmall Intestine CancerUnspecified Adult Solid Tumor, Protocol Specific
- Locations
- 🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
CC-5013 in Treating Patients With Recurrent Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00036894
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2003-01-07
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00051116
- Locations
- 🇺🇸
Myeloma Institute University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT00046735
- Locations
- 🇺🇸
Wake Forest University, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.